Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | NPR1 | P16066 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923355 | 0.85 | GRM5 (0.39) | — | |
| SCHEMBL12059022 | 0.85 | GRM2 (0.39) | CTSDGRM2LRRK2BACE1BCL2A1 | |
| SCHEMBL12059079 | 0.84 | BCL2A1 (0.38) | CTSDGRM2BCL2A1 | |
| SCHEMBL6923104 | 0.80 | CACNA2D1 (0.43) | — | |
| SCHEMBL12059074 | 0.79 | LMNA (0.38) | BACE1BCL2A1TNKS2TGFBR1 | |
| SCHEMBL12059075 | 0.79 | GRM2 (0.37) | GRM2BRD4KCNH2NPR1 | |
| SCHEMBL6920638 | 0.79 | RAB9A (0.38) | GRM2KCNH2 | |
| SCHEMBL12059033 | 0.78 | RAB9A (0.37) | GRM2LRRK2KCNH2MAP4K4 | |
| SCHEMBL6920969 | 0.78 | GRM2 (0.37) | GRM2BCL2A1BRD4KCNH2 | |
| SCHEMBL6921782 | 0.78 | GSK3A (0.36) | CTSDBACE1BCL2A1TNKS2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | CTSD 4089/4885GRM2 2/4885LRRK2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.